Company profile
Karyopharm Therapeutics Inc.
NASDAQ:KPTIBiotechnology: Pharmaceutical Preparations
Drug pipeline (3)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| SELINEXOR | approved | — | 32 | approved |
| ELTANEXOR | phase1_2 | — | 1 | no active trials |
| PADNARSERTIB | phase1 | — | 1 | terminated |
Revenue is the latest reported period from SEC filings. A combination product's amount appears on each of its constituent assets, so those rows are not additive.
Clinical trials (36)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT01896505 | phase1 | completed | 2013-07-30 | 2016-10-21 | Karyopharm Therapeutics Inc | A Phase I Trial to Assess the Effects of Food and Formulation on PK of KPT-330 in Patients With Sarcoma |
| NCT04442022 | phase2_3 | active_not_recruiting | 2020-09-03 | 2026-12-01 | Karyopharm Therapeutics Inc | A Study of Rituximab-Gemcitabine-Dexamethasone-Platinum (R-GDP) With or Without Selinexor in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma |
| NCT04414475 | phase2 | recruiting | 2020-07-01 | 2028-01-01 | Karyopharm Therapeutics Inc | A Study of Selinexor (Seli) + Low-dose Dexamethasone (LDD) in Penta-refractory Multiple Myeloma (MM), Seli and Bortezomib + LDD in Triple-class Refractory MM. |
| NCT05980806 | phase2 | recruiting | 2024-04-22 | 2027-06-01 | Karyopharm Therapeutics Inc | A Study of Selinexor Monotherapy in Subjects With JAK Inhibitor-naïve Myelofibrosis and Moderate Thrombocytopenia |
| NCT04421378 | phase1_2 | terminated | 2020-06-08 | 2023-07-03 | Karyopharm Therapeutics Inc | A Study of Selinexor in Combination With Standard of Care Therapy for Newly Diagnosed or Recurrent Glioblastoma |
FDA applications (1)
| Application | Type | Applicant | Products | |||
|---|---|---|---|---|---|---|
| NDA 212306 | NDA | KARYOPHARM THERAPEUTICS INC | ||||
Loading… | ||||||